NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Eledon Pharmaceuticals, Inc. (ELDN) Stock Analysis

Eledon Pharmaceuticals, Inc. (ELDN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ELDN

$2.26

+$0.00 (+0.22%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ELDN with… →

ELDN Key Statistics

As of Oct 21, 2026
Trading
Open
$2.25
Previous Close
$2.26
Day's Range
2.24–2.33
52-Week Range
1.35–4.60
Volume
625.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$183.65M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.90
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$45.62M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
81.26M
1-Year Return
−35.24%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
921.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ELDN closed at $2.26, −35.24% over 1 year.

Eledon Pharmaceuticals, Inc. (ELDN) has a market capitalization of $183.65M.

In fiscal 2025, ELDN reported revenue of $0.00.

ELDN Stock Return by Calendar Year

Eledon Pharmaceuticals, Inc. (ELDN) 10-year return: what $10,000 became

1 year
$10,000 $6,476
−35.24%
5 years
$10,000 $4,185
−58.15%
10 years
$10,000 $100
−99.00%

If you had invested $10,000 in Eledon Pharmaceuticals, Inc. (ELDN) 10 years ago, at the close on October 21, 2016, it would have been worth $100 at the close on October 21, 2026: −99.00% in total, −36.88% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+49.67%
2025−63.35%
2024+128.89%
2023−21.05%
2022−48.30%
2021−71.36%
2020+47.51%
2019−63.75%
2018−60.59%
2017−53.87%
2016 (partial year)−19.84%

As of October 21, 2026.

ELDN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$45.62M—
2024$0.00−$36.18M—
2023$0.00−$116.54M—
2022$0.00−$87.97M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$83.25M−$45.62M—
2024$0.00—−$70.58M−$36.18M—
2023$0.00—−$43.00M−$116.54M—
2022$0.00—−$39.78M−$87.97M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Eledon Pharmaceuticals, Inc. (ELDN) at $183.65M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 33 employees.

The most recent close on file for ELDN is $2.26, dated October 21, 2026. That is $0.00 (+0.22%) against the previous close. The 52-week range on file runs from $1.35 to $4.60. The latest close sits 67.41% above that 52-week low.

Financial Health

In fiscal 2025, Eledon Pharmaceuticals, Inc. reported revenue of $0.00. The same year closed with a net loss of $45.62M. Earnings per share on a trailing basis come to −0.9.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.85. Daily returns over the trailing 10 years annualize to a volatility of 105.98%. Over the trailing twelve months the total return is −35.24%. Across 10 years the annualized return works out at −36.88%.

Growth & Income

No dividend is on file for ELDN.

Across the complete calendar years on file, 2024 returned +128.89% and 2021 returned −71.36%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +49.67% year to date.

Peer Comparison

Eledon Pharmaceuticals, Inc. (ELDN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Eledon Pharmaceuticals, Inc. ELDN $183.65M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Eledon Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Visit website →